Uncategorized

Saol boards FDA’s resubmission boat, armed with new survival data

Published

on

Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version